Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
The relevance of 8 contemporary classification and grading systems for ductal carcinoma in situ (DCIS) of the breast was examined in 100 tumors by comparing DCIS grade with grade of the concurrent infiltrating ductal carcinoma (IDC). Besides tumor size and nodal status, the immunohistochemical parameters in both lesions were compared, including estrogen receptor, progesterone receptor, c-erbB-2 protein, E-cadherin, vimentin, Ki-67 (MIB1), and p27. Nuclear grading of DCIS alone or in combination with architectural pattern and necrosis showed the best correlation with grade of the invasive component. There also was a positive correlation between every biologic marker expressed in DCIS and in the concurrent IDC, supporting a clonal relationship. Biologic markers varied between the different grades of DCIS. DCIS is heterogeneous, and the progression of DCIS to IDC may be from low-grade DCIS to low-grade IDC and high-grade DCIS to high-grade IDC. This concept is different from the conventional model held for intraepithelial neoplasia in the cervix, vulva, vagina, and skin, in which there is increasing severity of in situ atypia (dysplasia) before the development of stromal invasion.
Leong
A S
AS
Hunter Area Pathology Services and the Discipline of Anatomical Pathology, University of Newcastle, Newcastle, Australia.
Sormunen
R T
RT
Vinyuvat
S
S
Hamdani
R W
RW
Suthipintawong
C
C
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000145:classification / Q000473:pathology; D002278:Carcinoma in Situ / Q000737:chemistry* / Q000145:classification / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000145:classification / Q000473:pathology; D002467:Cell Nucleus / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008840:Microfilament Proteins / Q000032:analysis; D008954:Models, Biological; D009124:Muscle Proteins; D009336:Necrosis; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D008840:Microfilament Proteins; D009124:Muscle Proteins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C058992:Tagln protein, mouse